U.S. Pharmaceuticals & Biotech Breakout Stocks

Crinetics Pharmaceuticals

Market Cap: US$4.1b

A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

SELLAS Life Sciences Group

Market Cap: US$2.5b

A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.

MeiraGTx Holdings

Market Cap: US$1.2b

A clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases.

ORIC Pharmaceuticals

Market Cap: US$1.1b

A clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States.

Sana Biotechnology

Market Cap: US$1.1b

A biotechnology company, focuses on utilizing engineered cells as medicines in the United States.

Solid Biosciences

Market Cap: US$1.0b

Develops therapies for neuromuscular and cardiac diseases in the United States.

Nika Pharmaceuticals

Market Cap: US$808.7m

Engages in the development and distribution pharmaceutical products for dietary supplements and antiviral drugs in the United States.

Prime Medicine

Market Cap: US$702.6m

A biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States.

REGENXBIO

Market Cap: US$676.7m

A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.

Tectonic Therapeutic

Market Cap: US$617.8m

A biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs).

Editas Medicine

Market Cap: US$560.1m

A clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.

Fate Therapeutics

Market Cap: US$339.2m

A clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.

Foghorn Therapeutics

Market Cap: US$294.2m

A clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.

Precision BioSciences

Market Cap: US$203.3m

A clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.

Vaxart

Market Cap: US$146.7m

A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.

ProMIS Neurosciences

Market Cap: US$120.6m

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.

Anixa Biosciences

Market Cap: US$106.8m

A biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.

Polyrizon

Market Cap: US$25.8m

A biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.

BetterLife Pharma

Market Cap: US$19.0m

A biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada.

Brainstorm Cell Therapeutics

Market Cap: US$15.9m

A biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases.

TransCode Therapeutics

Market Cap: US$7.3m

A clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers.

Panacea Life Sciences Holdings

Market Cap: US$4.2m

Operates as a holding company, researchers, develops, manufactures, produces, and distributes cannabinoids, mushrooms, kratom, and other natural, plant-based ingredients and products for humans and animals.

Universe Pharmaceuticals

Market Cap: US$3.6m

Through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China.

OMID Holdings

Market Cap: US$3.4m

A health and wellness company, engages in the manufacture and sale of CBD-based products.

Vaccinex

Market Cap: US$2.7m

A clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders.

Nutra Pharma

Market Cap: US$2.1m

A biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases in the United States.

Hepion Pharmaceuticals

Market Cap: US$1.7m

A biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States.

CBD of Denver

Market Cap: US$1.1m

Engages in developing and commercializing cannabidiol (CBD) products.

PAO Group

Market Cap: US$382.0k

Focuses on alternative patient care treatments.

Cannonau

Market Cap: US$72.5k

Engages in the provision of cannabidiol based products.

U.S. Stem Cell

Market Cap: US$66.2k

Engages in the research, development, and commercialization of stem cell and regenerative treatments in the United States and internationally.

Petlife Pharmaceuticals

Market Cap: US$44.4k

Engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States.

Clever Leaves Holdings

Market Cap: US$175.0

Operates in the botanical cannabinoid and nutraceutical industries.